Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer

Previous preclinical study has shown that high levels of ascorbic acid (AA) possesses the ability to kill human colorectal cancer cells and high expression of GLUT3 will augment the efficacy of AA. To date, no previous studies have investigated the combination of therapeutic role of AA and PD-L1 antibody in metastatic colorectal cancer with high expression of GLUT3. This protocol is a randomized controlled study of AA infusions combined with Adebrelimab and FOLFOX +/- bevacizumab versus treatment with FOLFOX +/- bevacizumab alone in metastatic colorectal cancer patients with high expression of

Trial Details

NCT ID

NCT04516681

Phase

PHASE3

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

• Ascorbic acid
• FOLFOX Protocol
• Adebrelimab

Locations (sample)

• Shanhai, Shanghai Municipality, China|31.14019,121.06417

Key Eligibility Criteria

• Age≥18 years, ≤75 years; Histologically proven peritoneal metastatic adenocarcinoma of colorectal cancer, unresectable metastatic disease; IHC conf…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →